Subjects not able to give informed consent 
Left Bundle Branch Block 
Thrombolytic therapy within 24 hours before randomization 
Oral anticoagulation with International Normalized Ratio (INR) > 2 
Known platelets < 100.000/µl or known hemorrhagic diathesis 
Stroke or Transient Ischemic Attack (TIA) within the past 6 months or any permanent residual neurological defect 
Evidence of an active gastrointestinal or urogenital bleeding 
Major surgery within 6 weeks 
History of allergic reaction to abciximab or eptifibatide or any component used in the study (including contrast media) 
Known severe renal (creatinine clearance <30ml/min) or hepatic insufficiency as well as Alanine transaminase (ALT)/aspartate transaminase (AST) elevations = 3xUpper limit normal (ULN); isolated AST-elevation is not considered an exclusion criteria from study participation 
Severe concomitant disease with life expectation < 1 year 
Subject has participated in any study using an investigational drug or device within 30 days or within 5 half-lives of the investigational drug (whichever is longer) of entry into this study. 
Subjects who will be inaccessible due to geographic or social factors during treatment or follow-up 
In France, a subject is neither affiliated with nor a beneficiary of a social security category.       
    

NCT00426751_exc_T1
Condition
Left Bundle Branch Block
NCT00426751_exc_T2
Procedure
Thrombolytic therapy
NCT00426751_exc_T3
Temporal
within 24 hours before randomization
NCT00426751_exc_T4
Procedure
Oral anticoagulation
NCT00426751_exc_T5
Measurement
International Normalized Ratio (INR)
NCT00426751_exc_T6
Value
> 2
NCT00426751_exc_T7
Measurement
platelets
NCT00426751_exc_T8
Value
< 100.000/µl
NCT00426751_exc_T9
Condition
hemorrhagic diathesis
NCT00426751_exc_T10
Condition
Transient Ischemic Attack (TIA)
NCT00426751_exc_T11
Condition
Stroke
NCT00426751_exc_T12
Scope
Stroke or Transient Ischemic Attack (TIA)
NCT00426751_exc_T13
Temporal
within the past 6 months
NCT00426751_exc_T14
Condition
residual neurological defect
NCT00426751_exc_T15
Condition
gastrointestinal bleeding
NCT00426751_exc_T16
Condition
urogenital bleeding
NCT00426751_exc_T17
Temporal
active
NCT00426751_exc_T18
Scope
gastrointestinal or urogenital bleeding
NCT00426751_exc_T19
Temporal
within 6 weeks
NCT00426751_exc_T20
Procedure
Major surgery
NCT00426751_exc_T21
Condition
allergic reaction
NCT00426751_exc_T22
Observation
History
NCT00426751_exc_T23
Drug
abciximab
NCT00426751_exc_T24
Drug
eptifibatide
NCT00426751_exc_T25
Drug
component used in the study
NCT00426751_exc_T26
Drug
contrast media
NCT00426751_exc_T27
Scope
abciximab or eptifibatide or any component used in the study (including contrast media)
NCT00426751_exc_T28
Measurement
creatinine clearance
NCT00426751_exc_T29
Value
<30ml/min
NCT00426751_exc_T30
Condition
hepatic insufficiency
NCT00426751_exc_T31
Measurement
Alanine transaminase (ALT)
NCT00426751_exc_T32
Measurement
aspartate transaminase (AST)
NCT00426751_exc_T33
Value
elevations
NCT00426751_exc_T34
Value
3xUpper limit normal (ULN)
NCT00426751_exc_T35
Condition
renal insufficiency
NCT00426751_exc_T36
Scope
creatinine clearance <30ml/min
NCT00426751_exc_T37
Scope
Alanine transaminase (ALT)/aspartate transaminase (AST) elevations = 3xUpper limit normal (ULN)
NCT00426751_exc_T38
Condition
Severe disease
NCT00426751_exc_T39
Measurement
life expectation
NCT00426751_exc_T40
Value
< 1 year
NCT00426751_exc_T41
Qualifier
severe
NCT00426751_exc_T42
Temporal
concomitant
NCT00426751_exc_T43
Observation
participated in any study
NCT00426751_exc_T44
Drug
investigational drug
NCT00426751_exc_T45
Device
device
NCT00426751_exc_T46
Scope
investigational drug or device
NCT00426751_exc_T47
Temporal
of the investigational drug within 30 days
NCT00426751_exc_T48
Temporal
within 5 half-lives of the investigational drug
NCT00426751_exc_T49
Reference_point
of the investigational drug
NCT00426751_exc_T50
Scope
within 30 days or within 5 half-lives of the investigational drug
NCT00426751_exc_T51
Observation
inaccessible
NCT00426751_exc_T52
Temporal
during treatment or follow-up
NCT00426751_exc_T53
Reference_point
treatment
NCT00426751_exc_T54
Reference_point
follow-up
NCT00426751_exc_T56
Negation
not
NCT00426751_exc_T58
Mood
able to
NCT00426751_exc_T59
Reference_point
randomization